Skip to main contentSkip to navigationSkip to search

Press release

Camurus to provide an update on the progress of its research and development programs at the Jefferies 2016 Healthcare Conference

11 November 2016

Lund — 11 November 2016 — Camurus AB (Nasdaq Stockholm; CAMX) today announces that Camurus is scheduled to present at the Jefferies 2016 London Healthcare Conference on November 16 at 5:20 pm local time (GMT).

Fredrik Tiberg, President and CEO, Camurus will provide an update on the company’s development pipeline, including the ongoing Phase 3 program for the weekly and monthly buprenorphine depots (CAM2038) for treatment of opioid dependence and pain. An update on the strategic priorities will also be provided, including the building of the European commercial organization in preparation for the anticipated launch of CAM2038 for treatment of opioid dependence in 2018.

Camurus has made good progress in accelerating its portfolio in therapeutic areas of addiction, pain, endocrinology and cancer, with a recent addition of three new drug candidates in clinical development. Camurus’ clinical stage pipeline comprises 10 programs developed alone or together with international pharmaceutical and biotech partners; including Novartis, Braeburn Pharmaceuticals and Rhythm. Results from a pivotal Phase 3 efficacy study of weekly and monthly buprenorphine depots for treatment of opioid dependence are expected during the fourth quarter 2016. An updated development pipeline table is available at

The audio and slide presentation will be webcasted live and can be accessed via Camurus web site

About Camurus
Camurus is a Swedish research-based pharmaceutical company committed to developing and commercializing innovative and differentiated medicines for the treatment of severe and chronic conditions. New drug products with best-in-class potential are conceived based on the proprietary FluidCrystal® drug delivery technologies and an extensive R&D expertise. Camurus’ clinical pipeline includes products for treatment of cancer, endocrine diseases, pain and addiction, developed in-house and in collaboration with international pharmaceutical companies. The company’s shares are listed on Nasdaq Stockholm under the ticker “CAMX”. For more information, visit

For more information
Fredrik Tiberg, President & CEO
Tel. +46 (0)46 286 46 92

Rein Piir, VP Investor Relations
Tel. +46 (0)70 853 72 92

The information was submitted for publication at 08.00 a.m. CET on 11 November 2016.

TypeError: Cannot read properties of undefined (reading 'url')